Terns Pharmaceuticals, INC Form 4 insider transactions

Director Robert Azelby reports the cancellation of stock options following the completion of the merger between Terns Pharmaceuticals and Merck.

Director Heather D. Turner reports the cancellation and cash-out of stock options following the completion of Terns Pharmaceuticals' acquisition by Merck.

Director Radhika Tripuraneni reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Director Jill M. Quigley reports the cancellation and conversion of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Director Jeffrey B. Kindler reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Director David A. Fellows reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Chief Medical Officer Emil Kuriakose reports the disposition of all equity holdings following the completion of Terns Pharmaceuticals' acquisition by Merck.

Terns Pharmaceuticals' CFO Andrew Gengos reported the disposition of common stock and stock options following the company's merger with Merck Sharp & Dohme LLC at $53 per share.

Amy L. Burroughs, CEO of Terns Pharmaceuticals, reported transactions related to the company's merger with Merck Sharp & Dohme LLC, detailing the conversion of stock options and restricted stock units.

Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose sold 942 shares of common stock for tax withholding purposes.

Terns Pharmaceuticals CEO Amy L. Burroughs exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Terns Pharmaceuticals CEO Amy L. Burroughs reported the exercise of stock options and subsequent sale of common stock totaling 14,583 shares under a pre-arranged 10b5-1 trading plan.

Terns Pharmaceuticals director Heather D Turner elected to receive stock options valued at $45,000 in lieu of her 2026 cash retainer.

Terns Pharmaceuticals director Radhika Tripuraneni elected to receive 1,697 stock options in lieu of a $45,000 cash retainer for 2026, aligning her interests with shareholders.

Terns Pharmaceuticals Director Robert Azelby elected to receive 1,697 stock options with a $34.6 exercise price in lieu of his 2026 cash retainer fee.

Terns Pharmaceuticals Director Jill M. Quigley elected to receive stock options valued at $45,000 in lieu of her 2026 cash retainer fee.

Terns Pharmaceuticals director Jeffrey B Kindler elected to receive a stock option grant in lieu of his 2026 cash retainer fee.

Terns Pharmaceuticals Director David A. Fellows elected to receive 2,828 stock options with a $34.6 exercise price in lieu of his 2026 cash retainer fee.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, was granted 56,250 Restricted Stock Units and 112,500 stock options as part of an incentive plan.

Terns Pharmaceuticals' CFO, Andrew Gengos, received significant equity awards, including 68,750 Restricted Stock Units and options for 137,500 shares, as part of his compensation.

Terns Pharmaceuticals CEO Amy L. Burroughs reported the acquisition of new equity awards and the exercise and sale of shares under a pre-arranged 10b5-1 trading plan.

Terns Pharmaceuticals CEO Amy L. Burroughs reported the exercise of stock options and vesting of restricted stock units, alongside a tax-related sale of shares.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 1,155 shares of common stock on January 2, 2026, to cover tax liabilities from restricted stock unit vesting.

Terns Pharmaceuticals Director Jill M. Quigley exercised stock options and subsequently sold 24,520 shares of common stock on November 4, 2025, as part of a pre-arranged trading plan.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 944 shares of common stock to cover tax liabilities from a restricted stock unit vesting.

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 853 shares of common stock to cover tax liabilities associated with a restricted stock unit award vesting.

Terns Pharmaceuticals' Chief Financial Officer, Andrew Gengos, acquired 10,000 shares of common stock through open market purchases on June 27, 2025, increasing his direct beneficial ownership to 25,000 shares.

Terns Pharmaceuticals, Inc. CEO and Director Amy L. Burroughs has acquired 23,314 shares of common stock, increasing her direct beneficial ownership in the company.

Terns Pharmaceuticals, Inc.'s Chief Financial Officer, Andrew Gengos, has acquired 15,000 shares of common stock through open market purchases in mid-June 2025, signaling strong insider confidence.

Radhika Tripuraneni, a Director at Terns Pharmaceuticals, Inc., has acquired 45,000 stock options with an exercise price of $4.10, vesting on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting.